M&A Deal Summary |
|
|---|---|
| Date | 2011-06-21 |
| Target | EraGen Biosciences |
| Sector | Life Science |
| Buyer(s) | Luminex |
| Sellers(s) | First Analysis |
| Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1995 |
| Sector | Medical Products |
| Employees | 1,325 |
| Revenue | 417M USD (2020) |
Luminex is a developer, manufacturer and marketer of proprietary instruments and assays utilizing xMAP open-architecture, multi-analyte platform and MultiCode real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex was founded in 1995 and is based in Austin, Texas.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 4 |
| Sector (Life Science) | 1 of 3 |
| Type (Add-on Acquisition) | 1 of 3 |
| State (Wisconsin) | 1 of 1 |
| Country (United States) | 1 of 3 |
| Year (2011) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-07-09 |
GenturaDx
Austin, Texas, United States GenturaDx, Inc. is a molecular diagnostic company focused on developing and manufacturing high-performance molecular diagnostic products that are both affordable and practical for any laboratory. |
Buy | - |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1981 |
| PE ASSETS | 800M USD |
| Size | Middle-Market |
| Type | Sector Agnostic |
First Analysis is a financial advisory and investment firm. First Analysis' private equity arm targets investments in growth companies at all stages of development. The Group looks for opportunities based primarily in the US and can commit up to $10 million of equity per transaction. Sectors of particular interest include outsourced services, (business/government services, education, environmental services, healthcare services, marketing services); information technology, (business integration, call centers, healthcare IT, network security, open source, sensor systems, transaction processing); and chemistry enabled businesses (advanced materials, chemicals, healthcare products, polymers, purification). First Analysis was formed in 1981 and is based in Chicago, Illinois.
| DEAL STATS | # |
|---|---|
| Overall | 48 of 71 |
| Sector (Life Science) | 2 of 2 |
| Type (Add-on Acquisition) | 35 of 51 |
| State (Wisconsin) | 1 of 2 |
| Country (United States) | 48 of 70 |
| Year (2011) | 4 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-04-21 |
Trustwave
Chicago, Illinois, United States Trustwave is a cybersecurity company that reduces cyber risk and fortifies organizations against disruptive and damaging cyber threats. The company's comprehensive offensive and defensive cybersecurity portfolio detects what others cannot, responds with greater speed and effectiveness, optimizes its client’s cyber investment, and improves security resilience. It is an analyst-recognized leader in managed detection and response (MDR), managed security services (MSS), cyber advisory, penetration testing, database security, and email security. Trustwave was formed in 1995 and is based in Chicago, Illinois. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-07-12 |
CSA Medical
Lexington, Massachusetts, United States CSA Medical develops and sells an innovative energy-based medical console that delivers a therapeutic spray of liquid nitrogen to freeze and destroy unwanted tissue in the body. This proprietary interventional platform, the Spray Cryotherapy System, is comprised of a device and specialty catheters that allow delivery of therapeutic doses of the cryogen. CSA Medical was formed in 1993 and is based in Lexington, Massachusetts. |
Buy | - |
